NCT06495307终止1 期
A PHASE I PROSPECTIVE OPEN LABEL STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 µG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) FOR THE TREATMENT OF OCULAR GRAFT-VERSUS-HOST DISEASE (OGVHD)
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 3
- 主要终点
- To assess the safety of rhPRG4 by observation of the frequency and severity of treatment-emergent adverse events
研究概览
简要总结
rhPRG4-GVHD-001 is a prospective multi-center study conducted in Australia to evaluate the safety and efficacy of topically-applied rhPRG4 in subjects with moderate to severe dry eye secondary to chronic GVHD.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 90 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis and Main Criteria for Inclusion:
- •All to be queried and checked at the screening visit (V1):
- •Subjects 18 years of age or older;
- •Subjects diagnosed with oGVHD for at least 3 months (current use of artificial tears for the treatment of GVHD);
- •VAS Eye Dryness (100-point scale) score ≥ 60 mm;
- •Tear Osmolarity ≥ 312 in either eye;
- •Corneal staining score with fluorescein ≥ 2 using the Oxford scale in the worst performing eye; staining must include quadrants beyond only inferior or superior staining;
- •Only subjects who satisfy all Informed Consent requirements may be included in the study.
排除标准
- •Diagnosis and Main Criteria for Exclusion:
- •Evidence of an active ocular infection in either eye;
- •History or presence of ocular surface disorders not related to oGVHD in either eye, including but not limited to significant conjunctivochalasis, superior limbic keratoconjunctivitis, limbal stem cell deficiency, allergic conjunctivitis, giant papillary conjunctivitis, atopic keratoconjunctivitis, anterior basement membrane dystrophies, neurotrophic keratitis, corneal dystrophy, exposure keratitis and moderate to severe blepharitis;
- •History of any ocular surgery (including laser or refractive surgical procedures) in either eye within 90 days before study enrollment. Ocular surgery will not be allowed during the study treatment period and elective ocular surgery procedures should not be planned during the duration of the follow-up period;
- •Initiation of new therapeutic modalities within 30 days of recruitment;
- •Artificial rescue tears are allowed as long as they are recorded in a diary;
- •Known hypersensitivity to one of the components of the study or procedural medications;
- •Participation in another clinical study at the same time as the present study or within 60 days of screening/baseline visit;
- •History of drug, medication or alcohol abuse or addiction;
- •Females of childbearing potential (those who are not surgically sterilized or post-menopausal for at least 1 year) are excluded from participation in the study if they meet any one of the following conditions:
- •are currently pregnant or,
- •have a positive result on the urine pregnancy test at the Screening/Baseline Visit or,
- •intend to become pregnant during the entire course of and 30 days after the study treatment periods, or,
- •are breast-feeding or,
- •not willing to use highly effective birth control measures, such as: Hormonal contraceptives - oral, implanted, transdermal, or injected and/or mechanical barrier methods, during the entire course of and 30 days after the study treatment periods.
研究组 & 干预措施
Treatment
Experimental
干预措施: rhPRG4 (Drug)
结局指标
主要结局
To assess the safety of rhPRG4 by observation of the frequency and severity of treatment-emergent adverse events
时间窗: 28
To assess the efficacy of rhPRG4 using the average VAS score assessing subjects' eye dryness (Question: Rate the dryness of your eye; anchors: 0 = no discomfort, 100 = maximal discomfort) at Day 28
时间窗: 28
To assess the efficacy of rhPRG4 using the total corneal staining with fluorescein (Oxford Scale) at Day 28
时间窗: 28
次要结局
- To assess the efficacy of rhPRG4 using the average VAS score for foreign body sensation, burning/stinging, itching, pain, sticky feeling, blurred vision and photophobia and total VAS (anchors: not at all & very)(28)
- To assess the efficacy of rhPRG4 using the maximum inter-eye tear osmolarity: max(OU)(28)
- To assess the efficacy of rhPRG4 using the absolute difference in inter-eye tear film breakup time (TBUT): min(OU)osmolarity: abs(OD - OS)(28)
- To assess the safety of rhPRG4 by observation of the Best Corrected Visual Acuity (BCVA)(28)
- To assess the safety of rhPRG4 by observation of intraocular pressure (IOP)(28)
- To assess the efficacy of rhPRG4 by NIH Eye Score(28)
- To assess the safety of rhPRG4 by observation of signs evaluated by slit lamp (SLE)(28)
- To assess the efficacy of rhPRG4 using the number of instillations of rescue artificial tear per day(28)
- To assess the efficacy of rhPRG4 using a patient questionnaire(28)
研究者
相似试验
招募中
1 期
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid TumorsAdvanced Solid TumorNCT05932862Exelixis429
进行中（未招募）
1 期
A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001)Advanced or Metastatic Solid TumorsNCT05382325Merck Sharp & Dohme LLC70
已完成
4 期
A Study of Epoetin Beta Treatment in Anemic Participants With Myelodysplastic Syndrome (MDS)Myelodysplastic SyndromesNCT02145026Hoffmann-La Roche100
已完成
4 期
The Safety, Pharmacokinetic Profile and Efficacy of Raltegravir in HIV-infected Patients at Least 60 Years of AgeHIVNCT01335620Imperial College London19
招募中
1 期
Study of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid TumorsMalignant MesotheliomaMetastatic Malignant Solid TumorAdvanced Solid TumorNCT06566079InSilico Medicine Hong Kong Limited160